Staphylococcal Scalded Skin SyndromeMANAGEMENT

DERMATOLOGY PRESENTATIONS · 12 SECTIONS

⚲

614 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Allergic contact dermatitis Bullous Pemphigoid Cutaneous Abscess DRESS syndrome Eczema Herpeticum Erysipelas Erythema multiforme Henoch-Schönlein purpura Herpes Zoster (Shingles)Herpetic Whitlow Hidradenitis suppurativa Paronychia Pediculosis (Lice)Pemphigus Vulgaris Pilonidal Abscess Pressure injury Psoriasis (acute flare)Psoriasis Flare Staphylococcal Scalded Skin Syndrome Stevens-Johnson Syndrome (SJS)Toxic Epidermal Necrolysis (TEN)Urticaria (acute)Warfarin-induced Skin Necrosis

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp60

Immediate priorities

›Skin failure recognition

›Extensive desquamation with large body surface area involvement

›Significant insensible fluid losses resembling burn physiology

›Temperature dysregulation from barrier loss

›Signs of secondary sepsis

›Tachycardia, hypotension, or altered mental status

›Lactate >= 2 mmol/l or signs of organ dysfunction

›Neonatal high-risk features

›Age < 1 month with diffuse skin involvement

›Hypothermia or feeding intolerance

›Stabilization priorities

›Secure IV access early

›Avoid denuded skin for line insertion

›Umbilical venous catheter in neonates when peripheral access fails

›Initiate IV antibiotics within 1 hour if sepsis features present

›Class I recommendation

›Anti-staphylococcal beta-lactam as first-line

›Fluid resuscitation for burn-like losses

›IV crystalloid if oral intake insufficient

›Maintenance plus replacement for losses through denuded skin

›Key diagnostic branch point

›Mucosal involvement present

›Raises concern for toxic epidermal necrolysis

›Urgent dermatology consultation and skin biopsy

›No mucosal involvement, superficial peeling, positive Nikolsky sign

›Clinical diagnosis of SSSS favored

›Treat empirically while confirming focus of infection

02History/hx61

Presentation pattern

›Prodromal features

›Fever, irritability, and malaise

›Preceding blistering by 24 to 48 hours

›Out-of-proportion skin tenderness early

›Skin pain and tenderness

›Exquisite cutaneous sensitivity

›Often precedes visible blistering

›Skin progression sequence

›Erythema beginning in skin folds and periorificial areas

›Flaccid bullae formation

›Widespread superficial desquamation in head-to-toe direction

›Preceding infection source

›Impetigo or skin infection

›Crusted lesions at site of primary infection

›Often remote from site of desquamation

›Conjunctivitis

›Purulent eye discharge

›Periorbital erythema

›Upper respiratory infection

›Recent URI, sore throat, or otitis

›Rhinorrhea or cough

›Wound or surgical site infection

›Umbilical stump infection in neonates

›Perianal infection

Risk factors

›Host susceptibility

›Age < 6 years

03Physical Exam/exam64

Vitals and general

›Hemodynamic stability snapshot

›Temperature

›Fever common but not universal

›Hypothermia in neonates suggests instability

›Heart rate

›Tachycardia most common vital sign abnormality

›True septic shock pattern is atypical for uncomplicated SSSS

›Blood pressure

›Usually within normal limits in uncomplicated pediatric cases

›Hypotension as marker of secondary sepsis or fluid deficit

›Respiratory rate

›Elevation may indicate pain, fever, or secondary pneumonia

›General appearance

›Irritability and inconsolability

›Skin pain elicited with minimal handling

›Refusal to be touched

›Hydration status

›Dry mucous membranes

›Decreased skin turgor over uninvolved areas

Skin examination

›Characteristic skin findings

›Diffuse tender erythema

›Beginning in flexural folds (axillae, groin, neck)

›Periorificial distribution around mouth, eyes, and nose

›Flaccid thin-walled bullae

›Easily ruptured

›Superficial, not tense

04Differential Diagnosis/ddx52

Life-threatening mimics

›Toxic epidermal necrolysis

›ICD-10 L51.2

›Drug exposure history required

›Mucosal involvement present

›Full-thickness epidermal necrosis on biopsy

›Subepidermal cleavage plane

›Necrotic keratinocytes

›Mortality 20 to 30% in adults

›Stevens-Johnson syndrome

›ICD-10 L51.1

›Drug-related, target lesions

›Mucosal erosions

›Epidermal detachment < 10% BSA

›Overlap with TEN at 10 to 30% BSA

›Staphylococcal sepsis with skin findings

›ICD-10 A41.01

›Hemodynamic instability distinguishes

›Blood cultures positive

Localized vs disseminated staphylococcal disease

›Bullous impetigo

›ICD-10 L01.03

›Same toxin mechanism, localized to infection site

›No positive Nikolsky sign at distant sites

›Does not spread beyond primary lesion

›Impetigo (non-bullous)

›ICD-10 L01.01

›Superficial crusting without systemic toxin effect

05Laboratory Tests/lt39

Microbiological studies

›Bacterial cultures from infection foci

›Swabs from conjunctivae, nasopharynx, perioral, perianal, wounds, umbilicus

›Higher yield than blood cultures

›Identifies toxin-producing Staphylococcus aureus

›Sensitivity and antibiotic susceptibility testing

›Identifies MRSA requiring vancomycin

›High clindamycin resistance rates (52 to 85%) in SSSS isolates

›Skin swab from blister base

›Lower yield than focal infection site swabs

›Toxin is produced remotely; blisters are sterile

›Blood cultures

›Routine blood cultures not recommended in healthy children

›Typically sterile in uncomplicated pediatric SSSS

›Risk of false-positive results and overtreatment

›Indicated in adults, immunocompromised, or sepsis features

›Two sets prior to antibiotics when feasible

›Positive blood cultures prompt broader sepsis workup

Routine blood work

›Complete blood count

›Leukocytosis common but non-specific

›Does not alter diagnosis or management in typical pediatric cases

›2025 systematic review: routine labs do not improve outcomes in SSSS

›Leukopenia as marker of severe illness or secondary sepsis

›Metabolic panel and renal function

›Electrolytes for dehydration and fluid replacement guidance

›Sodium, potassium correction targets

›Creatinine and BUN

06Diagnostic Tests/dt54

Scoring Systems

›No validated disease-specific scoring tool for SSSS

›Clinical diagnosis based on history and examination

›Abrupt onset, skin tenderness, positive Nikolsky sign

›Periorificial distribution, mucous membrane sparing

›BSA involvement estimation used for fluid management

›Rule of Nines adapted for age in pediatric patients

›Lund-Browder chart for more precise pediatric BSA estimation

›Severity stratification for disposition

›Mild: limited BSA, tolerating oral intake, hemodynamically stable

›Outpatient or short observation possible in reliable families

›Moderate: moderate BSA, dehydration, unable to maintain intake

›Inpatient admission required

›Severe: extensive BSA, sepsis features, adult presentation

›ICU-level care; consult burn team

MRI

›MRI role in SSSS

›No routine MRI indication for uncomplicated SSSS

›Diagnosis is clinical and microbiological

›Imaging not required to confirm superficial epidermal split

›Potential use in deep-seated infection identification

›Osteomyelitis or septic arthritis as concurrent source

›Necrotizing fasciitis exclusion in atypical presentations

›Limitations

›Availability and patient cooperation

›Not first-line for soft tissue infection in this context

›CT imaging indications

07Disposition/dispo39

Admission indications

›Inpatient admission criteria

›Inability to maintain oral hydration

›Perioral pain limiting fluid intake

›Vomiting or marked refusal

›Extensive BSA involvement

›Significant insensible losses requiring IV fluid management

›Wound care needs exceeding home capability

›Neonates and young infants

›Age < 3 months

›Higher risk of temperature dysregulation and secondary infection

›All adults with SSSS

›Mortality 40 to 63%

›Comorbidity management required

›ICU-level care indications

›Sepsis or hemodynamic instability

›Vasopressor requirement

›Lactate >= 2 mmol/l with clinical deterioration

›Extensive skin failure

›BSA involvement comparable to major burn

›Requires burn unit expertise

›Adult patients with comorbid renal failure or immunosuppression

›Rapid clinical deterioration possible

Discharge criteria

›Outpatient eligibility criteria

›Hemodynamically stable

›Normal vital signs for age

›No tachycardia at rest

08Treatment/t69

Antibiotic therapy

›First-line: IV beta-lactam

›Cefazolin IV preferred over nafcillin/oxacillin

›25 to 33 mg/kg/dose IV every 8 hours (pediatric)

›1 to 2 g IV every 8 hours (adult)

›Fewer infusion-related adverse effects than nafcillin

›Class I recommendation for anti-staphylococcal coverage

›Oxacillin or nafcillin IV if cefazolin unavailable

›Nafcillin 150 to 200 mg/kg/day divided every 6 hours (pediatric)

›Phlebitis risk requires adequate dilution and slow infusion

›MRSA coverage indications

›Vancomycin IV

›15 mg/kg/dose IV every 6 hours (pediatric; adjust to target AUC/MIC)

›15 to 20 mg/kg IV every 8 to 12 hours (adult)

›Trough or AUC-guided monitoring per institutional protocol

›Indication: high local MRSA prevalence, prior MRSA colonization, failure of beta-lactam

›Clindamycin: not recommended

›High resistance rates in SSSS isolates (52 to 85%)

›Systematic review: no outcome benefit despite anti-toxin theory

›Oral step-down when clinically improved

›Cephalexin PO

›25 to 50 mg/kg/day divided every 6 to 8 hours (pediatric)

›500 mg PO every 6 hours (adult)

›Dicloxacillin PO

›25 mg/kg/day divided every 6 hours (pediatric)

›500 mg PO every 6 hours (adult)

›Duration: 7 to 10 days total course in uncomplicated cases

09Special Populations/sp58

Pregnancy

›Pregnancy-specific considerations

›SSSS in pregnancy is rare; usually adult risk factors apply

›Immunological changes of pregnancy may alter susceptibility

›Exfoliative toxin clearance may be altered by pregnancy-related renal physiology

›Antibiotic selection in pregnancy

›Cefazolin: safe in all trimesters

›Preferred first-line IV agent

›Oxacillin: generally considered safe but limited data

›Vancomycin if MRSA suspected

›Monitor renal function and drug levels

›Avoid clindamycin given resistance data

›Fetal monitoring

›Maternal fever and systemic illness require fetal heart rate monitoring

›Viable gestation warrants obstetric consultation

›Wound care adaptation

›Positioning considerations to avoid supine hypotension

›Fluid resuscitation targets adjusted for pregnancy physiology

Geriatric

›Older adult features

›Adult SSSS mortality 40 to 63% due to comorbidities

›Renal insufficiency impairs exfoliative toxin clearance

›Immunosenescence reduces anti-toxin antibody response

›Antibiotic dosing adjustments

›Cefazolin: renally dose-adjusted

›CrCl 10 to 30 mL/min: 1 g IV every 12 hours

›Vancomycin: AUC-guided monitoring essential

›Renal toxicity risk higher in older adults

10Background/b64

Epidemiology

›Incidence and demographic distribution

›Annual incidence approximately 7.67 per million U.S. children

›British Journal of Dermatology epidemiologic data

›Highest rates in infants < 2 years: ~45 per million

›Seasonal pattern

›Higher incidence in summer and autumn

›Mirrors impetigo seasonality

›Sex and race distribution

›Female sex slightly more common

›Lower rates in Black children compared to White children

›Mortality

›Pediatric mortality approximately 0.3%

›Excellent prognosis with prompt treatment

›Adult mortality 40 to 63%

›Driven by underlying comorbidities

›Renal failure and immunosuppression key contributors

Pathophysiology

›Toxin-mediated mechanism

›Exfoliative toxins A and B (ETA and ETB)

›Produced by phage group II Staphylococcus aureus

›ETA encoded on bacterial chromosome

›ETB encoded on plasmid

›Target: desmoglein 1

›Serine protease activity cleaves desmoglein 1

›Same target as pemphigus foliaceus autoantibodies

›Desmoglein 1 expressed in superficial epidermis

›Result: intraepidermal split at stratum granulosum

11Patient Discharge Instructions/pdi33

copy discharge instructions

›Skin care at home

›Gentle sponge baths with lukewarm water

›Avoid scrubbing or rubbing peeling skin

›Pat dry gently with soft towel

›Apply prescribed emollient or wound dressing as instructed

›Keep denuded areas covered to prevent secondary infection

›Change dressings daily or as directed

›Avoid harsh soaps, perfumed products, and adhesive bandages on healing skin

›Medications

›Complete the full course of antibiotics even if skin looks better

›Do not stop early

›Give pain reliever as directed for skin discomfort

›Acetaminophen or ibuprofen as recommended by your doctor

›Do not use any steroid creams unless specifically prescribed

›Feeding and hydration

›Cool, soft foods and liquids are easiest with mouth sores

›Popsicles, yogurt, cool soup

›Ensure adequate fluid intake

›Monitor wet diapers in infants (at least 4 per day)

›Return to ER warning signs

›New blistering or skin peeling spreading

›Fever persisting or returning after 48 hours of antibiotics

›Child refusing all fluids or showing signs of dehydration

›Dry mouth, no tears, no wet diapers in 8 hours

›Skin looks infected with increasing redness, warmth, or pus

›Difficulty breathing

›Child becoming very sleepy or hard to wake

12References/r21

Guidelines and key sources

›Primary clinical references

›Pediatric Emergency Care systematic review on SSSS management

›Routine blood cultures and routine labs not recommended in healthy pediatric patients

›British Journal of Dermatology epidemiologic study

›Annual incidence 7.67 per million; highest in infants < 2 years

›European Academy of Dermatology and Venereology adult SSSS review

›Adult mortality 40 to 63%; IVIG not routinely recommended

›Pediatric Dermatology systematic review on antibiotic selection

›Clindamycin not recommended due to resistance and lack of outcome benefit

›Cefazolin preferred over nafcillin for IV therapy

Evidence and coding

›Pathophysiology references

›NEJM review on exfoliative toxin mechanism and TEN differentiation

›Subepidermal vs intraepidermal cleavage plane biopsy findings

›Mucosal involvement distinguishes TEN from SSSS

›Pediatric Dermatology review on desmoglein 1 cleavage

›ETA and ETB serine protease mechanism

›Coding standards

›ICD-10 L00 staphylococcal scalded skin syndrome

›ICD-10 L51.2 toxic epidermal necrolysis (key differential)

›ICD-10 L01.03 bullous impetigo (localized form of same toxin mechanism)

›SNOMED CT staphylococcal scalded skin syndrome disorder concept

Learn More: Staphylococcal Scalded Skin Syndrome→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.